Country: Canada
Language: English
Source: Health Canada
DAPAGLIFLOZIN
PRO DOC LIMITEE
A10BK01
DAPAGLIFLOZIN
10MG
TABLET
DAPAGLIFLOZIN 10MG
ORAL
15G/50G
Prescription
Active ingredient group (AIG) number: 0156370002; AHFS:
APPROVED
2023-05-16
Page PRO-DAPAGLIFLOZIN (Dapagliflozin) 1 of 79 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR PRO-DAPAGLIFLOZIN Dapagliflozin Tablets Tablets, 5 mg and 10 mg, Oral ATC Code: A10BK01 Sodium-glucose co-transporter 2 (SGLT2) inhibitors PRO DOC LTÉE. 2925, boul. Industriel Laval, Quebec H7L 3W9 Submission Control Number: 273946 Date of Initial Authorization: MAY 03, 2023 PRO-DAPAGLIFLOZIN (Dapagliflozin) Page 2 of 79 RECENT MAJOR LABEL CHANGES Not applicable. TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ............................................................................................... 2 TABLE OF CONTENTS ................................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ......................................................................... 4 1 INDICATIONS ................................................................................................................. 4 1.1 Pediatrics .......................................................................................................................... 4 1.2 Geriatrics .......................................................................................................................... 4 2 CONTRAINDICATIONS .................................................................................................... 5 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ................................................................ 5 4 DOSAGE AND ADMINISTRATION .................................................................................... 5 4.1 Dosing Considerations ..................................................................................................... 5 4.2 Recommended Dose and Dosage Adjustment ............................................................... 6 4.5 Missed Dose ............................................................................. Read the complete document